Immunotherapy for Cancer — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cancer immunotherapy harnesses, enhances, or restores the immune system's natural ability to detect and destroy cancer cells. Unlike chemotherapy (which indiscriminately kills rapidly dividing cells) and targeted therapy (which inhibits specific oncogenic pathways), immunotherapy activates the immune system to recognise cancer as foreign — creating durable, sometimes lifelong anti-tumour immunity in responding patients.

The landmark development of immune checkpoint inhibitors — antibodies blocking PD-1/PD-L1 and CTLA-4 inhibitory pathways — transformed oncology from the early 2010s. Pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) received FDA approval in 2014–2015 and have since transformed outcomes in melanoma, non-small cell lung cancer, bladder cancer, head and neck cancer, Hodgkin's lymphoma, MSI-high solid tumours, and many other malignancies. The 2018 Nobel Prize in Physiology or Medicine was awarded to James Allison and Tasuku Honjo for the discovery of cancer therapy by inhibition of negative immune regulation — specifically CTLA-4 and PD-1 checkpoint pathways.

Immunotherapy now spans multiple classes: immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4 antibodies), CAR-T cell therapy (genetically engineered patient T-cells), bispecific antibodies (blinatumomab), cancer vaccines (sipuleucel-T), cytokines (IL-2, interferon-alpha), and tumour-infiltrating lymphocyte (TIL) therapy. The field is rapidly evolving — more than 4,000 active clinical trials in oncologic immunotherapy are registered globally as of 2025.

• Non-small cell lung cancer (NSCLC): Pembrolizumab + chemotherapy (carboplatin-paclitaxel/pemetrexed) is first-line standard of care for most NSCLC regardless of PD-L1 expression (KEYNOTE-189/407). Pembrolizumab monotherapy for PD-L1 ≥50% tumour proportion score (TPS) — KEYNOTE-024: median OS 26 months vs. 14 months with chemotherapy. Nivolumab + ipilimumab (CheckMate-9LA) is an additional approved first-line option.
• Melanoma: The original checkpoint inhibitor success story. Ipilimumab (anti-CTLA-4) increased 5-year OS from 20% to 20–28%. Pembrolizumab and nivolumab achieve objective response in 40–45% of metastatic melanoma and 5-year OS of ~34–44%. Combination ipilimumab + nivolumab: 5-year OS ~52% in metastatic melanoma (CheckMate-067).
• MSI-high / dMMR solid tumours: Pembrolizumab is FDA-approved for any MSI-H/dMMR solid tumour regardless of tumour type ('tumour-agnostic' indication). ORR ~36–43% across tumour types; durable responses. Identified by mismatch repair testing on tumour biopsy.
• Bladder/urothelial cancer: Atezolizumab and pembrolizumab as second-line post-platinum chemotherapy; pembrolizumab + enfortumab vedotin (antibody-drug conjugate) approved first-line, achieving ORR 68%, mOS 31 months.
• Head and neck squamous cell carcinoma (HNSCC): Pembrolizumab ± chemotherapy for first-line recurrent/metastatic HNSCC; pembrolizumab monotherapy for CPS ≥20 achieves significantly superior OS to chemotherapy alone (KEYNOTE-048).
• Classical Hodgkin's lymphoma: Nivolumab and pembrolizumab achieve ORR 65–70% in relapsed/refractory classical Hodgkin's lymphoma post-ASCT — one of the highest checkpoint inhibitor response rates.
• Colorectal cancer (MSI-H): Pembrolizumab vs. chemotherapy first-line for MSI-H/dMMR metastatic CRC (KEYNOTE-177): mPFS 16 months vs. 8 months. First-line immunotherapy standard for this 4–5% of CRC patients.
• CAR-T indicated cancers: Tisagenlecleucel (DLBCL, ALL), axicabtagene ciloleucel (DLBCL, follicular lymphoma), lisocabtagene maraleucel (DLBCL), ide-cel/cilta-cel (multiple myeloma), brexucabtagene autoleucel (mantle cell lymphoma, B-ALL).

Biomarker testing before immunotherapy:

• PD-L1 expression (by IHC — 22C3 or 28-8 assay): guides pembrolizumab vs. chemotherapy + pembrolizumab decision in NSCLC; required before pembrolizumab in HNSCC and urothelial cancer
• MSI/dMMR testing (IHC for MMR proteins or PCR for microsatellite instability): identifies patients who respond to pembrolizumab regardless of tumour type
• TMB (tumour mutational burden): High TMB (≥10 mutations/megabase) predicts pembrolizumab response across tumour types (KEYNOTE-158 pan-tumour trial)
• HER2, BRAF, EGFR, ALK status for NSCLC: patients with actionable driver mutations (EGFR, ALK, ROS1) generally do not benefit from checkpoint inhibitors as first-line — targeted therapy preferred

Patient fitness criteria:

• ECOG performance status 0–2 for clinical trial eligibility; PS 3 may be considered in exceptional circumstances if immunotherapy is the only active option
• Autoimmune disease: active severe autoimmune disease is a relative contraindication to checkpoint inhibitors (risk of flare and immune-related adverse events); stable, well-controlled autoimmune conditions may be treated with careful monitoring
• Prior organ transplant: checkpoint inhibitors carry significant risk of allograft rejection — requires careful risk-benefit discussion with transplant team
• Active corticosteroid use (≥10 mg prednisone equivalent/day): may blunt checkpoint inhibitor efficacy; taper to <10 mg before starting where possible
• HIV: no longer contraindicated — patients with well-controlled HIV (CD4 >200, undetectable viral load) can receive checkpoint inhibitors with similar efficacy and safety profile to HIV-negative patients

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

• Durable long-term responses: The defining advantage of immunotherapy over chemotherapy. Checkpoint inhibitor responses are maintained in 20–30% of patients for 5+ years even after treatment discontinuation — a phenomenon virtually unknown with chemotherapy. Pembrolizumab 5-year OS in metastatic melanoma: 34%; for NSCLC high PD-L1 expressors: 32% at 5 years (KEYNOTE-001).
• Cure in previously incurable cancers: Metastatic melanoma was uniformly fatal with median OS of 9 months in the pre-checkpoint inhibitor era. With ipilimumab + nivolumab, 5-year OS is 52% — likely representing cure in a substantial proportion (CheckMate-067). Metastatic MSI-H colorectal cancer: pembrolizumab achieves first-line median PFS of 16 months vs. 8 months with chemotherapy with more durable long-term benefit.
• Manageable toxicity profile compared to chemotherapy: Checkpoint inhibitors lack the myelosuppression, alopecia, and mucositis of chemotherapy. The principal toxicity class — immune-related adverse events (irAEs) — is distinct and manageable with corticosteroids in most cases. Approximately 20–30% of patients develop grade 3–4 irAEs requiring treatment modification; irAE-related deaths occur in <0.5% of patients.
• CAR-T cell transformational responses: Tisagenlecleucel in paediatric ALL: ORR 81% in relapsed/refractory disease (ELIANA trial). Axicabtagene ciloleucel in relapsed/refractory DLBCL: ORR 82%, CR 54% — responses that are durable at 5 years in approximately 40% of patients.
• Tumour-agnostic applications: The FDA approval of pembrolizumab for MSI-H/dMMR cancers represents the first 'histology-independent' oncology approval — based on biomarker rather than tumour type. Patients with any MSI-H solid tumour — including rare cancers (small bowel, biliary tract) with no other effective therapy — can access pembrolizumab.

• Immune-related adverse events (irAEs): The principal toxicity class of checkpoint inhibitors, caused by non-specific immune activation affecting normal tissues. Any organ can be affected; common irAEs include: Dermatitis/rash (20–40%, usually manageable); Colitis (diarrhoea, 10–20%; grade 3–4 in 2–5%); Hepatitis (2–5%; grade 3–4 in <2%); Pneumonitis (2–5%; most dangerous irAE — early recognition essential); Endocrinopathies (hypothyroidism 8–15%; hypophysitis 2–5%; type 1 diabetes <1%); Nephritis (1–2%); Myocarditis (rare, <1% — highest fatality rate of irAEs at 25–50%). Most irAEs respond to systemic corticosteroids (prednisolone 1–2 mg/kg/day); severe irAEs require hospitalisation and may need infliximab, mycophenolate, or other immunosuppressants. Endocrinopathies (hypothyroidism, adrenal insufficiency) are typically permanent and require lifelong hormone replacement.
• Hyperprogression: Paradoxical rapid tumour growth after PD-1 blockade initiation occurs in approximately 10–15% of patients. Associated with EGFR mutation, MDM2/MDM4 amplification, and high age. Mechanism unclear but may involve Fc receptor-mediated activation of tumour-associated macrophages.
• Infusion reactions: Occur in 5–15% of patients with checkpoint inhibitors and antibody-based immunotherapy. Usually mild-moderate (fever, chills, urticaria) and managed by slowing infusion rate and antihistamines. Severe anaphylaxis: <0.5%.
• CAR-T specific toxicities: Cytokine release syndrome (CRS) — a systemic inflammatory syndrome from massive T-cell activation — affects 70–90% of CAR-T recipients; grade 3–4 CRS in 20–30%. Managed with tocilizumab (IL-6 receptor antagonist). Immune effector cell-associated neurotoxicity syndrome (ICANS) — neurological toxicity (confusion, aphasia, seizures, cerebral oedema) in 20–40%; grade 3–4 in 10–15%. Both require intensive monitoring in specialised CAR-T centres.
• Non-response and resistance: 50–70% of patients do not respond to PD-1/PD-L1 monotherapy. Primary resistance (never responding) and acquired resistance (initial response followed by progression) are major challenges. Combination strategies (checkpoint + chemotherapy, checkpoint + anti-VEGF, bispecific antibodies) are being studied to overcome resistance.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Immunotherapy costs are among the highest in medicine globally, primarily driven by checkpoint inhibitor drug costs. International patients seek access in countries with generic biosimilar availability or government-negotiated pricing:

• India: Pembrolizumab biosimilar (Pembro-Bio, Zydus) is available in India at approximately USD 800–1,200 per 200 mg infusion vs. USD 12,000–15,000 per infusion in the USA. A 24-month pembrolizumab course costs approximately USD 20,000–35,000 in India vs. USD 350,000–500,000 in the USA. India's generic pharmaceutical industry produces affordable biosimilar monoclonal antibodies with CDSCO approval. CAR-T therapy in India: USD 50,000–80,000 (NovartisKymriah biosimilar available) vs. USD 400,000–500,000 in the USA.
• Thailand: USD 3,000–5,000 per pembrolizumab infusion at Bangkok hospitals. Cheaper than Western countries; original branded products from Merck with verified supply chain.
• Turkey: USD 2,000–4,000 per infusion. Government insurance (SGK) covers approved indications for Turkish citizens. Private sector international patients: original drugs at negotiated prices.
• Germany / EU: EUR 6,000–10,000 per infusion for branded checkpoint inhibitors at private academic centres. NHS and EU statutory insurers negotiate lower rates. EU biosimilar pembrolizumab approvals underway.
• United States: USD 12,000–20,000 per pembrolizumab or nivolumab infusion (every 3–6 weeks). Annual checkpoint inhibitor cost: USD 100,000–250,000. Even with commercial insurance, biologic specialty tier co-pays can be USD 10,000–30,000/year. Patient Assistance Programs (Merck ACCESS, BMS Patient Assistance) available for uninsured/underinsured patients.
• United Kingdom (NHS): NICE-approved checkpoint inhibitors are funded on the NHS. Access to newer approvals via Cancer Drugs Fund. Private sector: GBP 7,000–12,000 per infusion.

Patients pursuing immunotherapy abroad should verify: biomarker testing capability (PD-L1, MSI/dMMR, TMB) to ensure appropriate patient selection; availability of both branded and biosimilar agents with verified supply chain; irAE management expertise including access to tocilizumab for severe CRS; and coordination with home country oncologist for continued monitoring and follow-up imaging.

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.